These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37966285)

  • 1. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
    Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
    Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
    Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
    Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of Solanezumab in Preclinical Alzheimer's Disease.
    Sperling RA; Donohue MC; Raman R; Rafii MS; Johnson K; Masters CL; van Dyck CH; Iwatsubo T; Marshall GA; Yaari R; Mancini M; Holdridge KC; Case M; Sims JR; Aisen PS;
    N Engl J Med; 2023 Sep; 389(12):1096-1107. PubMed ID: 37458272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer's disease trials.
    Abanto J; Dwivedi AK; Imbimbo BP; Espay AJ
    Brain; 2024 Oct; 147(10):3513-3521. PubMed ID: 39259179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
    N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
    Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
    N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donanemab in Early Alzheimer's Disease.
    Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
    N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
    Menegaz de Almeida A; Leite M; Lopes LM; Gomes Lima P; Siegloch Barros ML; Rocha Pinheiro S; Andrade Í; Viana P; Morbach V; Marinheiro G; de Oliveira R; Pinheiro AC
    Expert Rev Neurother; 2024 Sep; 24(9):929-936. PubMed ID: 38879828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab.
    Klein G; Delmar P; Kerchner GA; Hofmann C; Abi-Saab D; Davis A; Voyle N; Baudler M; Fontoura P; Doody R
    J Prev Alzheimers Dis; 2021; 8(1):3-6. PubMed ID: 33336218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Salloway S; Farlow M; McDade E; Clifford DB; Wang G; Llibre-Guerra JJ; Hitchcock JM; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Cruchaga C; Goate AA; Perrin RJ; Xiong C; Li Y; Morris JC; Snider BJ; Mummery C; Surti GM; Hannequin D; Wallon D; Berman SB; Lah JJ; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sánchez-Valle R; Brooks WS; Gauthier S; Galasko DR; Masters CL; Brosch JR; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Jack CR; Koeppe R; Snyder PJ; Aisen PS; Thomas RG; Berry SM; Wendelberger BA; Andersen SW; Holdridge KC; Mintun MA; Yaari R; Sims JR; Baudler M; Delmar P; Doody RS; Fontoura P; Giacobino C; Kerchner GA; Bateman RJ;
    Nat Med; 2021 Jul; 27(7):1187-1196. PubMed ID: 34155411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.